Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has reported a substantial increase in committed customer orders for its contract development and manufacturing organization (CDMO) business, alongside a recent financing that extends its operating runway. In a shareholder letter, CEO Amir Reichman outlined the company's progress, highlighting approximately $8.1 million in committed customer orders as of October 20, 2026—a more than 300% increase from $1.9 million at the end of 2025. This growth was driven by a new agreement with a U.S.-based biopharmaceutical company that includes about $5.1 million in committed base service fees. The agreement also contemplates up to $5.85 million in additional, uncommitted services, bringing the combined potential opportunity to over $10 million, subject to further agreements and project milestones.
The order growth matters because it demonstrates Scinai's ability to attract and retain CDMO clients, a key indicator of the viability of its service business. For a small biopharmaceutical company, a robust CDMO operation can provide a revenue stream that supports its therapeutic development efforts. The company also reported approximately $5.3 million in combined net proceeds from recent equity financings, including a standby equity purchase agreement drawdown and a private placement with warrant exercises. Management estimates that current cash resources and expected customer payments will support operations through late 2027, potentially extending into the third quarter of 2028 if additional project phases are activated and delivered. This extended runway reduces near-term financing risk and provides more time to execute on strategic priorities.
Scinai remains focused on expanding its CDMO customer base, improving facility utilization, and pursuing capital-efficient development of its NanoAb immunotherapy platform through grants and partnerships. The company's dual approach—combining service revenue with proprietary pipeline development—could offer a more sustainable path in the competitive biotech landscape. For investors, the disclosed figures offer concrete evidence of commercial momentum and financial stability. The full press release can be viewed at https://ibn.fm/3C1F4, and the latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI.
The announcement was distributed via InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio within IBN. InvestorWire provides wire-grade press release syndication and editorial syndication to 5,000+ outlets, along with press release enhancement and social media distribution to maximize reach. The platform also offers a full array of tailored corporate communications solutions. Full terms of use and disclaimers are available on the InvestorWire website at https://www.InvestorWire.com/Disclaimer.
